Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Evaluation of the Effectiveness of Boron Neutron Capture Therapy with Iodophenyl-Conjugated Closo-Dodecaborate on a Rat Brain Tumor Model

Version 1 : Received: 8 August 2023 / Approved: 8 August 2023 / Online: 9 August 2023 (02:33:46 CEST)

A peer-reviewed article of this Preprint also exists.

Fujikawa, Y.; Fukuo, Y.; Nishimura, K.; Tsujino, K.; Kashiwagi, H.; Hiramatsu, R.; Nonoguchi, N.; Furuse, M.; Takami, T.; Hu, N.; Miyatake, S.-I.; Takata, T.; Tanaka, H.; Watanabe, T.; Suzuki, M.; Kawabata, S.; Nakamura, H.; Wanibuchi, M. Evaluation of the Effectiveness of Boron Neutron Capture Therapy with Iodophenyl-Conjugated closo-Dodecaborate on a Rat Brain Tumor Model. Biology 2023, 12, 1240. Fujikawa, Y.; Fukuo, Y.; Nishimura, K.; Tsujino, K.; Kashiwagi, H.; Hiramatsu, R.; Nonoguchi, N.; Furuse, M.; Takami, T.; Hu, N.; Miyatake, S.-I.; Takata, T.; Tanaka, H.; Watanabe, T.; Suzuki, M.; Kawabata, S.; Nakamura, H.; Wanibuchi, M. Evaluation of the Effectiveness of Boron Neutron Capture Therapy with Iodophenyl-Conjugated closo-Dodecaborate on a Rat Brain Tumor Model. Biology 2023, 12, 1240.

Abstract

High-grade gliomas present a significant challenge in neuro-oncology because of their aggressive nature and resistance to current therapies. Boron neutron capture therapy (BNCT) is a potential treatment method; however, the boron carrier compounds used — such as 4-borono-L-phenylalanine (L-BPA) — have limitations. This study evaluated the use of boron-conjugated 4-iodophenylbutanamide (BC-IP), a novel boron compound in BNCT, for the treatment of glioma. Using in vitro drug exposure experiments and in vivo studies, we compared BC-IP and BPA, with a focus on boron uptake and retention characteristics. The results showed that although BC-IP had a lower boron uptake than BPA, it exhibited superior retention. Furthermore, despite lower boron accumulation in tumors, BC-IP showed significant survival improvement in glioma-bearing rats compared to controls. These results suggest that BC-IP, with its unique properties, may be an alternative boron carrier for BNCT. Further research is required to optimize this potential treatment modality, which could significantly contribute to advancing the treatment of high-grade gliomas.

Keywords

Boron neutron capture therapy (BNCT); High-grade glioma; Boron compound; Closo-dodecaborate

Subject

Biology and Life Sciences, Biology and Biotechnology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.